Menu
Search
|

Menu

Close
X

Dicerna Pharmaceuticals Inc DRNA.OQ (NASDAQ Stock Exchange Global Select Market)

11.92 USD
-- (--)
As of 1:30 AM IST
chart
Previous Close 11.92
Open --
Volume --
3m Avg Volume 203,465
Today’s High --
Today’s Low --
52 Week High 15.80
52 Week Low 2.69
Shares Outstanding (mil) 20.84
Market Capitalization (mil) 130.07
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.29 Mean rating from 7 analysts

KEY STATS

Revenue (mm, USD)
FY18
2
FY17
2
FY16
0
FY15
0
EPS (USD)
FY18
-0.301
FY17
-3.659
FY16
-2.873
FY15
-3.123
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.76
Price to Sales (TTM)
vs sector
191.28
5.73
Price to Book (MRQ)
vs sector
9.78
5.45
Price to Cash Flow (TTM)
vs sector
--
23.29
Total Debt to Equity (MRQ)
vs sector
0.00
16.72
LT Debt to Equity (MRQ)
vs sector
0.00
12.39
Return on Investment (TTM)
vs sector
-76.78
14.61
Return on Equity (TTM)
vs sector
-169.72
16.34

EXECUTIVE LEADERSHIP

David Madden
Independent Chairman of the Board, Since 2009
Salary: --
Bonus: --
Douglas Fambrough
President, Chief Executive Officer, Director, Since 2013
Salary: $430,000.00
Bonus: --
John Green
Chief Financial Officer, Principal Financial Officer, Since 2016
Salary: --
Bonus: --
Bob Brown
Senior Vice President, Chief Scientific Officer, Since 2012
Salary: $335,000.00
Bonus: --
Theodore Ashburn
Senior Vice President - Product Strategy & Operations, Since 2014
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

87 Cambridgepark Dr
CAMBRIDGE   MA   02140-2311

Phone: +1617.6218097

Dicerna Pharmaceuticals, Inc. is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined. The Company uses its RNAi technology platform to build a pipeline in these therapeutic areas. The Company develops dacryocystorhinostomy (DCR)-Primary Hyperoxaluria Type 1 (PH1) for the treatment of PH1 by targeting the gene encoding the liver enzyme glycolate oxidase. The Company uses its dicer substrate RNA (DsiRNA)-EX Conjugate technology to develop a subcutaneously injected treatment for PH1. The Company develops DCR-MYC for the treatment of MYC-related cancers, including hepatocellular carcinoma (HCC) and pancreatic neuroendocrine tumors (PNET).

SPONSORED STORIES